Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner - TradingView

Reuters | Oct. 27, 2025, 7:23 a.m. | Original
Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner TradingView
Brazil's MBRF signs investment deal with subsidiary of Saudi Arabia's PIF - TradingView China's September net gold imports via Hong Kong fall about 18% from August - TradingView